Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19
Sarah Lim, Christopher J. Tignanelli, Nicolas Hoertel, David R. Boulware, Michael Usher
Abstract
This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.
Topics & Concepts
MedicineRitonavirCoronavirus disease 2019 (COVID-19)CohortPediatricsEmergency medicineInternal medicineDiseaseIntensive care medicineHuman immunodeficiency virus (HIV)Family medicineAntiretroviral therapyViral loadInfectious disease (medical specialty)COVID-19 Clinical Research StudiesInfectious Encephalopathies and EncephalitisSARS-CoV-2 and COVID-19 Research